Meta-analysis of adrenocortical tumour genomics data: Novel pathogenic pathways revealed

Oncogene

Volumn 29, Issue 21, 2010, Pages 3163-3172

  Szabo P M ^a   Tamasi V ^a   Molnar V ^a   Andrasfalvy M ^b   Tombol Z ^a   Farkas, R ^a   Kovesdi K ^a   Patocs A ^a   Toth M ^a   Szalai, C ^a,c   Falus, A ^a   Racz K ^a   Igaz, P ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Kromat Ltd Co   (Hungary)

^c HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

Author keywords

Adrenocortical tumour; Comparative genome hybridization; Meta analysis; MRNA profiling; Pathway analysis

Indexed keywords

LIPOPOLYSACCHARIDE; MESSENGER RNA; RETINOIC ACID; TOLL LIKE RECEPTOR 4;

ADRENAL CORTEX TUMOR; ANTIGEN PRESENTATION; ARTICLE; CANCER TISSUE; CELL CYCLE PROGRESSION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; COMPLEMENT SYSTEM; COMPUTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; META ANALYSIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADRENAL CORTEX NEOPLASMS; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; META-ANALYSIS AS TOPIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 77952953203     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.80     Document Type: Article

References (49)

1. Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S et al. (2003). Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 63: 5308-5319.
2. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F. (2005). Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 90: 3886-3896.
3. Bourcigaux N, Gaston V, Logie A, Bertagna X, Le Bouc Y, Gicquel C. (2000). High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J Clin Endocrinol Metab 85: 322-330.
4. Cummins CL, Volle DH, Zhang Y, McDonald JG, Sion B, Lefrancois-Martinez AM et al. (2006). Liver X receptors regulate adrenal cholesterol balance. J Clin Invest 116: 1902-1912.
5. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R et al. (2005). Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90: 1819-1829.
6. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F et al. (2009). Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27: 1108-1115.
7. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P. (2000). Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28: 145-152.
8. El Akawi Z, Napoli JL. (1994). Rat liver cytosolic retinal dehydro-genase: comparison of 13-cis-, 9-cis-, and all-trans-retinal as substrates and effects of cellular retinoid-binding proteins and retinoic acid on activity. Biochemistry 33: 1938-1943.
9. Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Konsgen D et al. (2009). Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol 22: 579-588.
10. Fernandez-Ranvier GG, Weng J, Yeh RF, Shibru D, Khafnashar E, Chung KW et al. (2008a). Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J Surg 32: 873-881.
11. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C et al. (2008b). Identification of biomarkers of adrenocor-tical carcinoma using genomewide gene expression profiling. Arch Surg 143: 841-846.
12. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A et al. (2005). Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 90: 1332-1339.
13. Figueiredo BC, Cavalli LR, Pianovski MA, Lalli E, Sandrini R, Ribeiro RC et al. (2005). Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J Clin Endocrinol Metab 90: 615-619.
14. Figueiredo BC, Stratakis CA, Sandrini R, DeLacerda L, Pianovsky MA, Giatzakis C et al. (1999). Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab 84: 1116-1121.
15. Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. (2004). Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2: 4.
16. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J et al. (2009). Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15: 668-676.
17. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL et al. (2003). Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162: 521-531.
18. Haselbeck RJ, Ang HL, Deltour L, Duester G. (1997). Retinoic acid and alcohol/retinol dehydrogenase in the mouse adrenal gland: a potential endocrine source of retinoic acid during development. Endocrinology 138: 3035-3041. (Pubitemid 27258538)
19. Hong F, Breitling R. (2008). A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics 24: 374-382.
20. Kanczkowski W, Zacharowski K, Wirth MP, Ehrhart-Bornstein M, Bornstein SR. (2009). Differential expression and action of Toll-like receptors in human adrenocortical cells. Mol Cell Endocrinol 300: 57-65.
21. Kjellman M, Kallioniemi OP, Karhu R, Hoog A, Farnebo LO, Auer G et al. (1996). Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 56: 4219-4223.
22. Laurell C, Velazquez-Fernandez D, Lindsten K, Juhlin C, Enberg U, Geli J et al. (2009). Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur J Endocrinol 161: 141-152.
23. Libe R, Fratticci A, Bertherat J. (2007). Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14: 13-28.
24. Marx C, Wolkersdorfer GW, Brown JW, Scherbaum WA, Bornstein SR. (1996). MHC class II expression\a new tool to assess dignity in adrenocortical tumours. J Clin Endocrinol Metab 81: 4488-4491.
25. Ondrey F. (2009). Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemopreven-tion. Clin Cancer Res 15: 2-8.
26. Palsson-McDermott EM, ONeill LA. (2004). Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113: 153-162.
27. Patalano A, Brancato V, Mantero F. (2009). Adrenocortical cancer treatment. Horm Res 71: 99-104.
28. Russell AJ, Sibbald J, Haak H, Keith WN, McNicol AM. (1999). Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage. Br J Cancer 81: 684-689.
29. Scripture CD, Sparreboom A, Figg WD. (2005). Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6: 780-789.
30. Shimizu M, Takai K, Moriwaki H. 2009. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated reti-noid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 100: 369-374.
31. Sidhu S, Marsh DJ, Theodosopoulos G, Philips J, Bambach CP, Campbell P et al. (2002). Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 87: 3467-3474.
32. Skawran B, Steinemann D, Weigmann A, Flemming P, Becker T, Flik J et al. (2008). Gene expression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions. Mod Pathol 21: 505-516.
33. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A et al. (2006). Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 154: 587-598.
34. Soon PS, McDonald KL, Robinson BG, Sidhu SB. (2008). Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 13: 548-561.
35. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL et al. (2009). Microarray gene expression and immunohisto-chemistry analyses of adrenocortical tumors identify IGF-2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 16: 573-583.
36. Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM et al. (2008). Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 7: 425-431.
37. Subramaniam S, Stansberg C, Cunningham C. (2004). The interleukin 1 receptor family. Dev Comp Immunol 28: 415-428.
38. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550.
39. Thorngate FE, Strockbine PA, Erickson SK, Williams DL. (2002). Altered adrenal gland cholesterol metabolism in the apoE-deficient mouse. J Lipid Res 43: 1920-1926.
40. Tombol Z, Szabo P, Molnar V, Wiener Z, Tolgyesi G, Horanyi J et al. (2009). Integrative molecular-bioinformatics study of human adrenocortical tumors: microRNA, tissue specific target prediction and pathway analysis. Endocr Relat Cancer 16: 895-906.
41. Turnbull AV, Rivier CL. (1999). Regulation of the hypothalamic-pituitary- adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 79: 1-71.
42. Vakharia K, Hinson JP. (2005). Lipopolysaccharide directly stimulates cortisol secretion by human adrenal cells by a cyclooxygenase-dependent mechanism. Endocrinology 146: 1398-1402.
43. Velazquez-Fernandez D, Laurell C, Geli J, Hoog A, Odeberg J, Kjellman M et al. (2005). Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138: 1087-1094.
44. West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, Pianovski MA et al. (2007). Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67: 600-608.
45. Wolkersdorfer GW, Marx C, Brown J, Schroder S, Fussel M, Rieber EP et al. (2005). Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma. J Clin Endocrinol Metab 90: 1768-1774.
46. Ye P, Mariniello B, Mantero F, Shibata H, Rainey WE. (2007). G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol 195: 39-48.
47. Zacharowski K, Zacharowski PA, Koch A, Baban A, Tran N, Berkels R et al. (2006). Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci USA 103: 6392-6397.
48. Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P. (2002). Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 34: 48-57.
49. Zhao J, Speel EJ, Muletta-Feurer S, Rutimann K, Saremaslani P, Roth J et al. (1999). Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 155: 1039-1045.